LIN vs NRIX · P/E 34, rev $33.99B vs rev $54.5M
Linde plc Ordinary Shares (LIN) versus Nurix Therapeutics Inc (NRIX) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Nurix Therapeutics Inc (NRIX) is a biotechnology company listed on NASDAQ.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported NRIX revenue for 2024-11-30 was $54.5M. Net income was -$193.6M. Revenue was down 29.1% from 2023-11-30 to 2024-11-30. NRIX currently screens at market cap $1.77B.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. NRIX currently screens at market cap $1.77B.
Not investment advice. Open the LIN and NRIX stock pages for the full models.
Not investment advice.